Combines Insilico's Pharma.AI platform with Bora's global development, manufacturing, quality, and commercialization capabilities to explore a next-generation drug innovation model
CAMBRIDGE, Mass. and TAIPEI, July 14, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd. ("Bora"; TWSE: 6472; OTCQX: BORAY), a global leader in pharmaceutical manufacturing.
The proposed alliance will be governed by definitive agreements to be discussed and executed by Insilico and Bora and is designed to combine Insilico's proprietary Pharma.AI platform, spanning target discovery, generative chemistry, and molecule optimization, with Bora's global development, manufacturing, quality, and commercialization capabilities. By linking AI-enabled discovery with automation-driven development, manufacturing, and quality execution, Insilico and Bora aim to pioneer a next-generation drug innovation model that connects novel molecule design with the capabilities required to develop, manufacture, and deliver medicines to patients with unmet medical needs.
The alliance lays the foundation for a broad, multi-target collaboration framework, subject to the parties' further discussion and execution of definitive agreements. If fully implemented, the potential value of the proposed collaboration could exceed US$2.5 billion. Insilico expects to support Bora in strengthening AI capabilities across its global workforce and enhancing AI literacy across the organization. The partnership is also expected to apply Insilico's AI capabilities to improve efficiency across manufacturing, supply chain, distribution, and corporate operations. As the collaboration progresses, Bora and Insilico expect to further refine its scope, scale, and operating framework.
As part of the alliance, Insilico aims to accelerate Bora's transition toward more AI-driven and automation-driven drug discovery and development capabilities by providing comprehensive research and development strategies and end-to-end AI solutions across global discovery and development workflows. Over time, the alliance will further explore opportunities to apply AI and automation-driven approaches across development planning, process optimization, pharmaceutical development, manufacturing readiness, and quality systems.
The proposed alliance reflects a shared vision that the next generation of biopharmaceutical innovation will be increasingly AI-native, data-rich, and automation-driven. In this new model, value will be created not only through the discovery and design of novel molecules, but also through smarter, more efficient translation of those molecules into high-quality development programs and, ultimately, medicines for patients. Insilico brings an AI-native discovery engine with demonstrated productivity across multiple therapeutic areas, while Bora brings deep experience in drug development, global manufacturing, quality systems, supply chain execution, and commercialization.